α-synuclein
α-Syn
α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-synuclein regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) and other neurodegenerative disorders. Accumulation of misfolded oligomers and larger aggregates of α-synuclein defines multiple neurodegenerative diseases called synucleinopathies, but the mechanisms by which α-synuclein acts in neurodegeneration are unknown.
α-synuclein Isoform Specific Products
All Product Categories
-
α-synuclein Inhibitors
(117)
View all products
-
α-synuclein Antagonists
(2)
View all products
-
α-synuclein Activator
(1)
View all products
-
α-synuclein Modulators
(2)
View all products
-
α-synuclein Inducers
(2)
View all products
-
α-synuclein Degraders
(11)
View all products
-
α-synuclein Control
(1)
View all products
-
α-synuclein Ligands
(6)
View all products
-
α-synuclein Related Products (157)
Related Products (157)
-
α-synuclein Isoform Comparison
-
KAC-50.1
0 ImagesCat. No.: HY-168647KAC-50.1 is an α-Synuclein (α-syn) PET ligand, with a KD of 35 nM toward site 2 in recombinant α-syn fibrils.
-
Multi-kinase-IN-14
0 ImagesCat. No.: HY-181046CAS No.: 2201083-51-2Multi-kinase-IN-14 is an orally active and blood-brain barrier-permeable multi-kinase inhibitor. Multi-kinase-IN-14 reduces the excessive phosphorylation of α-synuclein by inhibiting four kinases (ABL1, DYRK1A, GSK3β, and LRRK2) and stabilizing microtubules. Multi-kinase-IN-14 is applicable for research on neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease.
-
α-Synuclein-IN-24
0 ImagesCat. No.: HY-184819CAS No.: 2883627-56-1α-Synuclein-IN-24 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 4.0 μM. α-Synuclein-IN-24 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks reaggregation. α-Synuclein-IN-24 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-24 can be used for the research of Parkinson's disease.
-
Sulfamerazine (Standard)
0 ImagesSulfamerazine (Standard) is the analytical standard of Sulfamerazine. This product is intended for research and analytical applications. Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection.
-
Harmol (Standard)
0 ImagesHarmol (Standard) is the analytical standard of Harmol (HY-107811). This product is intended for research and analytical applications. Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model.
-
α-Synuclein-IN-25
0 ImagesCat. No.: HY-184847CAS No.: 2883627-66-3α-Synuclein-IN-25 is a quinone-acid hybrid and also an α-synuclein aggregation inhibitor with an IC50 of 3.0 μM. α-Synuclein-IN-25 dissociates preformed α-Syn aggregates, inhibits their re-aggregation, scavenges reactive oxygen species, and reduces the formation of α-Syn inclusions in neuronal cells. α-Synuclein-IN-25 can be used in the research of Parkinson's disease.
-
NAB2 (Standard)
0 ImagesCat. No.: HY-110174RCAS No.: 1504588-00-4NAB2 (Standard) is the analytical standard of NAB2 (HY-110174). This product is intended for research and analytical applications. NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficKing and mediates endosomal trafficKing events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficKing defects associated with early-onset ParKinson's disease.
-
α-Synuclein-IN-22
0 ImagesCat. No.: HY-184817CAS No.: 2883627-63-0α-Synuclein-IN-22 is an α-Synuclein inhibitor with an IC50 of 2.7 μM against human α-Syn. α-Synuclein-IN-22 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-22 scavenges ROS and shows low cytotoxicity. α-Synuclein-IN-22 can be used in research related to Parkinson's disease.
-
α-Synuclein-IN-23
0 ImagesCat. No.: HY-184818CAS No.: 2883627-62-9α-Synuclein-IN-23 is an inhibitor of α-synuclein with an IC50 of 2.1 μM. α-Synuclein-IN-23 dissociates preformed α-synuclein aggregates, scavenges reactive oxygen species (ROS), and inhibits the formation of α-synuclein inclusions in neuronal cells. α-Synuclein-IN-23 can be used for the research of Parkinson's disease.
-
α-Synuclein aggregate binder 3
0 ImagesCat. No.: HY-186234CAS No.: 2648041-95-4α-Synuclein aggregate binder 3 is a probe for α-synuclein aggregates. The Ki value of α-Synuclein aggregate binder 3 for binding to sonicated α-synuclein fibrils is 0.8 nM. α-Synuclein aggregate binder 3 can be used for α-synuclein imaging, as well as for detecting disorders associated with α-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
-
Scyllo-Inositol (Standard)
0 ImagesScyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease.
-
α-Synuclein modulator 1
0 ImagesCat. No.: HY-169288CAS No.: 3058709-40-0α-Synuclein modulator 1 (Compound 7k) is a modulator for α-synuclein. α-Synuclein modulator 1 exhibits a maximal absorption and emission wavelength of 386 and 603 nm in ACN/PBS (1:1) buffer.
-
Sulfamerazine sodium
0 ImagesSulfamerazine (RP2632) sodium is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine sodium inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine sodium inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine sodium can be used for the research of Parkinson’s disease and bacterial infection.
-
α-Synuclein-IN-21
0 ImagesCat. No.: HY-184816CAS No.: 2883627-65-2α-Synuclein-IN-21 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 1.6 μM. α-Synuclein-IN-21 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks re-aggregation. α-Synuclein-IN-21 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-21 can be used for the research of Parkinson's disease.
-
α-Synuclein-IN-19
0 ImagesCat. No.: HY-184782CAS No.: 1026937-99-4α-Synuclein-IN-19 is a polyphenolic acid monoamide derivative and an inhibitor of α-synuclein (α-Syn) aggregation. α-Synuclein-IN-19 can be used in Parkinson's disease-related research.
-
Phen-DC3
0 ImagesCat. No.: HY-15594CAS No.: 942936-75-6Phen-DC3 is a bisquinolinium G-quadruplex (G4) ligand. Phen-DC3 selectively binds to and stabilizes the hybrid quadruplex-duplex hybrid (QDH) derived from the PIM1 promoter. Phen-DC3 also binds to the c-myc promoter Pu24T G4 via extensive π-stacking, and induces polymerase stalling at α-synuclein DNA and RNA G4 sequences. Phen-DC3 Trifluoromethanesulfonate (HY-15594A) downregulates LPS (HY-D1056)-induced TNFRSF21, RIPK3 and p-MLKL in VECs, and ameliorates CLP-induced pulmonary vascular leakage in septic rats. Phen-DC3 can be used in studies related to neurodegenerative diseases and sepsis-associated vascular injury.
